Emodin (0.25 or 0.5 μg/ml) was reported to attenuate nonalcoholic fatty liver disease (NAFLD) in zebrafish by activating AMPK pathway, via improving PI3K/AKT2/AMPKα-mediated IR and enhancing AMPKα/PPARα/CPT1 and AMPKα/PPARα/ACOX1-mediated fatty acid oxidation [168]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.